Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Citius Pharmaceuticals is 'Strong Sell'. According to 2 analysts, the average rating for CTXR stock is "Strong Buy." The month stock price forecast is $, which is an increase of % from. Citius Pharmaceuticals started at buy with $4 stock price target at Maxim Group Strong Commercial Prospects. Aug. 13, at a.m. ET on TipRanks. Real time Citius Pharmaceuticals (CTXR) stock price quote, stock graph, news & analysis Buy Stock · Best Brokers for Beginners · Best Brokerage Accounts. If you are looking for stocks with good return, Citius Pharmaceuticals Inc stock can be a bad, high-risk 1-year investment option. Citius Pharmaceuticals Inc.
Is Citius Pharmaceuticals Stock Undervalued? The current Citius Pharmaceuticals [CTXR] share price is $ The Score for CTXR is 21, which is 58% below. Based on 2 Wall Street analysts who have issued ratings for Citius Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Strong Buy." Out. Broker Rating. Citius Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of on a scale of 1 to 5 (Strong Buy to Strong Sell). Earnings vs Market: CTXR is forecast to become profitable over the next 3 years, which is considered above average market growth. Earnings vs Market: CTXR is forecast to become profitable over the next 3 years, which is considered above average market growth. The latest analyst rating for Citius Pharma (NASDAQ:CTXR) was provided by EF Hutton, and Citius Pharma maintained their buy rating. Q. When was the last upgrade. Citius Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is , and is based on 1 buy rating. Based on the Citius Pharmaceuticals stock forecast, it's now a good time to buy CTXR stock because it's trading % below our forecast, and it could be. (CTXR) A Good Investment? The below Citius Pharmaceuticals Inc. (CTXR) share stock is a buy, sell or hold. Citius Pharmaceuticals Inc. Share Price. Research Analysis: CTXR. View More. Earnings Per Share. Consensus EPS. Analyst Recommendations. Strong Buy. Buy. Hold. Underperform. Sell. Analyst Price Targets. 0. Hold. 0. 0. 0. Underweight. 0. 0. 0. Sell. 0. 0. 0. Consensus. -. -. Buy. Stock Price Target CTXR. High, $ Median, $ Low, $ Average, $
Citius Pharmaceuticals (CTXR) reported Q3 earnings per share (EPS) of -$, meeting estimates of -$ by %. In the same quarter last year, Citius. The consensus among 2 Wall Street analysts covering (NASDAQ: CTXR) stock is to Strong Buy CTXR stock. Out of 2 analysts, 1 (50%) are recommending CTXR as a. View Citius Pharmaceuticals Inc CTXR stock quote prices, financial information, real-time forecasts, and company news from CNN. Invest in stocks, fractional shares, and crypto all in one place. Open An Account. View Disclosure. Average Recommendation, Buy. Average Target Price, Number Of Ratings, 3. FY Report Date, 9/ Last Quarter's Earnings, Citius Pharmaceuticals stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given period. Citius Pharmaceuticals Stock Smart Score ; Analyst Consensus. Moderate Buy. Average Price Target: $ (% Upside) ; Hedge Fund Trend. Decreased. By K. The average analyst rating for CTXR stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well. Based on 3 analysts giving stock ratings to CTXR in the past 3 months. Neutral. SellBuy. Strong sellStrong buy. Strong sellSellNeutralBuyStrong buy. Strong buy.
Get Wall Street analysts ratings for Citius Pharmaceuticals, Inc. (CTXR). Buy or Sell this stock? See what the analysts say Strong Buy Stocks - Short Squeeze. Overall, Citius Pharmaceuticals Inc stock has a Growth Grade of F, Momentum Grade of D. Whether or not you should buy Citius Pharmaceuticals Inc stock will. The latest consensus rating for CTXR is "Buy". This is the average recommendation of 8 analysts: 0 strong sell, 0 sell, 1 hold, 5 buy, 2 strong buy. In the. Technical analysis forecast for Citius Pharmaceuticals Stock is that its in a downtrend for shortterm, and I will avoid taking a BUY or a LONG trade in this. View analyst opinion as to whether the stock is a strong buy, strong sell or hold, based on analyst Month CTXR price targets. Created with Highcharts
Low Rate Credit Card For Balance Transfer | Metatrader 4 Us Brokers